Article
Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population.
Cancer chemotherapy and pharmacology - 1 May 2021
Saarenheimo Jatta, Wahid Nesna, Eigeliene Natalja, Ravi Ravichandra, Salomons Gajja S, Ojeda Matilde Fernandez, Vijzelaar Raymon, Jekunen Antti, van Kuilenburg André B P
Abstract excerpt
Capecitabine is a fluoropyrimidine that is widely used as a cancer drug for the treatment of patients with a variety of cancers. Unfortunately, early onset, severe or life-threatening toxicity is observed in 19-32% of patients treated with capecitabine and 5FU. Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in the degradation of 5FU and a DPD deficiency has been shown to be a major determinant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.